VasoGenix Pharmaceuticals, Inc. Awarded $400,000 by Kansas Bioscience Authority to Continue Development of its CGRP (Calcitonin Gene-Related Peptide) Analogs for Treating Heart Failure

LENEXA, Kan.--(BUSINESS WIRE)--VasoGenix Pharmaceuticals Inc. (www.vasogenix.net) announced today that it will be awarded $400,000 from the Kansas Bioscience Authority (KBA) to support ongoing development of VasoGenix’ CGRP (calcitonin gene-related peptide) agonist analogs for treating heart failure. KBA previously awarded VasoGenix $200,000 in 2008. KBA awards are matches to funds raised by the company through its financial advisor Einhorn and Associates of Milwaukee (414-453-4488). The Company is raising capital for the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration.